Company news

Esperion Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Esperion Reports First Quarter 2025 Financial Results

May 6, 2025

Esperion to Participate in The Citizens Life Sciences Conference

April 25, 2025

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

April 24, 2025

Esperion to Report First Quarter 2025 Financial Results on May 6

April 23, 2025

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

April 10, 2025

Esperion Appoints Robert E. Hoffman to Board of Directors

April 1, 2025

Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

March 24, 2025

Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

March 20, 2025

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

March 3, 2025

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

February 18, 2025

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11: 30 a.m. ET.

January 8, 2025

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

December 17, 2024

Esperion Announces $210 Million Convertible Debt Financing

December 12, 2024

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

December 11, 2024

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

December 1, 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

November 20, 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

November 17, 2024

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

November 6, 2024

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

November 3, 2024

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

October 30, 2024

Esperion to Report Third Quarter 2024 Financial Results on November 7

October 23, 2024

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

September 24, 2024

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

September 4, 2024

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

September 2, 2024

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

August 25, 2024

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

August 11, 2024

Esperion to Report Second Quarter 2024 Financial Results on August 12

July 24, 2024

Esperion to Participate in Upcoming BTIG Biotech Conference

July 23, 2024

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

July 15, 2024

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

June 27, 2024

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

May 21, 2024

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

May 19, 2024

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

May 13, 2024

Esperion Reports First Quarter 2024 Financial Results

May 6, 2024

Esperion to Participate in Upcoming May Investor Conferences

April 28, 2024

Esperion to Report First Quarter 2024 Financial Results on May 7

April 22, 2024

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

April 6, 2024

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

March 31, 2024

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

March 25, 2024

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

March 24, 2024

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

March 21, 2024

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

March 21, 2024

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

March 21, 2024

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

February 12, 2024

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

January 22, 2024

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

January 17, 2024

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

January 2, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.